EPIRUS BIOPHARMACEUTICALS

epirus-biopharmaceuticals-logo

EPIRUS is focusing on the central development of a broad pipeline of biosimilar monoclonal antibodies and therapeutic proteins, optimized for use within the SCALEโ„ข disposable manufacturing system, and designed to be deployed in an "In Market, For Market" โ„ข manufacturing configuration.

#SimilarOrganizations #People #Financial #Website #More

EPIRUS BIOPHARMACEUTICALS

Social Links:

Industry:
Biotechnology Life Science Therapeutics

Founded:
2000-03-28

Address:
Boston, Massachusetts, United States

Country:
United States

Website Url:
http://www.epirusbiopharma.com

Total Employee:
11+

Status:
Active

Contact:
6176073437

Email Addresses:
[email protected]

Total Funding:
83.08 M USD

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Font API WordPress Font Awesome Domain Not Resolving Sitelinks Search Box Organization Schema Yoast WordPress SEO Plugin Google Maps


Similar Organizations

axcella-logo

Axcella

Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.

excision-biotherapeutics-logo

Excision BioTherapeutics

Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.


Current Advisors List

daniel-turner_image

Daniel Turner Board of Director @ Epirus Biopharmaceuticals
Board_member

geoff-duyk_image

Geoff Duyk Board of Director @ Epirus Biopharmaceuticals
Board_member

scott-m-rocklage_image

Scott M. Rocklage Board of Director @ Epirus Biopharmaceuticals
Board_member

daotian-fu_image

Daotian Fu Board of Director @ Epirus Biopharmaceuticals
Board_member

kevin-buchi_image

Kevin Buchi Member of the Board of Directors @ Epirus Biopharmaceuticals
Board_member

kevin-forrest_image

Kevin Forrest Board Observer @ Epirus Biopharmaceuticals
Board_observer

Current Employees Featured

michael-wyand_image

Michael Wyand
Michael Wyand Senior Vice President of Clinical and Regulatory @ Epirus Biopharmaceuticals
Senior Vice President of Clinical and Regulatory

suman-patel_image

Suman Patel
Suman Patel Vice President of Manufacturing and Quality @ Epirus Biopharmaceuticals
Vice President of Manufacturing and Quality
2012-10-01

nick-plumeridge_image

Nick Plumeridge
Nick Plumeridge Senior Vice President of Business Development @ Epirus Biopharmaceuticals
Senior Vice President of Business Development

Stock Details


Company's stock symbol is NASDAQ:EPRSQ

Acquisitions List

Date Company Article Price
2015-09-09 Bioceros Bioceros acquired by Epirus Biopharmaceuticals 14.1 M USD
2014-07-15 Zalicus Zalicus acquired by Epirus Biopharmaceuticals N/A

Investors List

livzon-mabpharm_image

Livzon Mabpharm

Livzon Mabpharm investment in Series B - Epirus Biopharmaceuticals

tpg-biotech_image

TPG Biotech

TPG Biotech investment in Series B - Epirus Biopharmaceuticals

5am-ventures_image

5AM Ventures

5AM Ventures investment in Series B - Epirus Biopharmaceuticals

mousse-partners_image

Mousse Partners

Mousse Partners investment in Series B - Epirus Biopharmaceuticals

greenwoods-investment_image

Greenwoods Investment

Greenwoods Investment investment in Series B - Epirus Biopharmaceuticals

montreaux-equity-partners_image

Montreux Equity Partners

Montreux Equity Partners investment in Series B - Epirus Biopharmaceuticals

gibralt-capital-corporation_image

Gibralt Capital Corporation

Gibralt Capital Corporation investment in Series B - Epirus Biopharmaceuticals

adage-capital-management_image

Adage Capital Management

Adage Capital Management investment in Series B - Epirus Biopharmaceuticals

5am-ventures_image

5AM Ventures

5AM Ventures investment in Venture Round - Epirus Biopharmaceuticals

montreaux-equity-partners_image

Montreux Equity Partners

Montreux Equity Partners investment in Venture Round - Epirus Biopharmaceuticals

Official Site Inspections

http://www.epirusbiopharma.com

  • Host name: epirusbiopharma.com
  • IP address: 162.243.32.126
  • Location: New York United States
  • Latitude: 40.7308
  • Longitude: -73.9975
  • Metro Code: 501
  • Timezone: America/New_York
  • Postal: 10011

Loading ...

More informations about "Epirus Biopharmaceuticals"

Epirus Biopharmaceuticals - Crunchbase Company โ€ฆ

Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.See details»

Epirus Biopharmaceuticals - CB Insights

Epirus is building a global biosimilar enterprise to improve patient access to important medicines. The Company's strategy for commercial success relies on targeted approaches for diverse โ€ฆSee details»

EPIRUS Biopharmaceuticals Inc - Company Profile and News

Company profile page for EPIRUS Biopharmaceuticals Inc including stock price, company news, executives, board members, and contact informationSee details»

EPIRUS Biopharmaceuticals, Inc.

Explore EPIRUS Biopharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 23 clinical trials, 15 news, and 35 literature, Disease Domain ...See details»

Epirus Biopharma - Company Profile - Tracxn

Sep 19, 2024 Epirus Biopharma - Develops biosimilar monoclonal antibodies and therapeutic proteins. Public Company. Raised a total funding of $44.5M over 4 rounds from 16 investors.See details»

EPIRUS Biopharmaceuticals - Business Information - ZoomInfo

View EPIRUS Biopharmaceuticals (www.epirusbiopharma.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as โ€ฆSee details»

About EPIRUS - Epirus News

At Epirus we believe the informed use of pharmaceuticals and similar health supplements can be a helpful tool to increase mental and physical health, as well as success in all aspects of life โ€ฆSee details»

Epirus Biopharmaceuticals - M&A Summary and Business โ€ฆ

Epirus Biopharmaceuticalsโ€™ largest acquisition to date was in 2015, when it acquired Bioceros BV for $14M. Itโ€™s largest disclosed sale occurred in 2015, when it sold Zalicus Pharmaceuticals to โ€ฆSee details»

Epirus Biopharmaceuticals - VentureRadar

Oncobiologics is a privately-held biopharmaceutical company focused on developing and commercializing monoclonal antibody biosimilar therapeutics. It is advancing its pipeline of 11 โ€ฆSee details»

EPIRUS Biopharmaceuticals Joins Biosimilars Forum To Help โ€ฆ

Nov 5, 2015 For more information visit EPIRUSโ€™ website at www.epirusbiopharma.com. About the Biosimilars Forum The Biosimilars Forum is a nonprofit organization whose mission is to โ€ฆSee details»

EPIRUS Biopharmaceuticals, Inc. | Insights

Latest on EPIRUS Biopharmaceuticals, Inc. Already A Biomedtracker Subscriber?You have access to the full company record through your subscription.See details»

Boston-Based EPIRUS Biopharmaceuticals Reels In $36 Million

Apr 16, 2014 BOSTON--Epirus Biopharmaceuticals, Inc. (Epirus), a Boston-based biopharmaceutical company focused on the global development and commercialization of โ€ฆSee details»

Epirus Biopharmaceuticals - Contacts, Employees, Board Members ...

Epirus Biopharmaceuticals develops biosimilar monoclonal antibodies and therapeutic proteins for emerging markets.See details»

Epirus Biopharmaceuticals : and Polpharma Group Enter Into a โ€ฆ

Jul 14, 2015 "This profit-sharing collaboration with Polpharma Group enables us to better direct our business and retain future value," said Amit Munshi, president and chief executive officer, โ€ฆSee details»

Epirus grabs $36 mln Series B funds and merges with Zalicus

Apr 16, 2014 Epirus Biopharmaceuticals said Wednesday that it has secured $36 million in Series B funding. Livzon Mabpharm led the round with participation from other investors that โ€ฆSee details»

EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and โ€ฆ

BOSTON, Sept. 09, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and โ€ฆSee details»

EPIRUS Biopharmaceuticals Expands Biosimilar Pipeline and โ€ฆ

BOSTON, Sept. 09, 2015 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and โ€ฆSee details»

Epirus and Zalicus Announce Merger Agreement - Business Wire

Apr 16, 2014 After an extensive review of potential merger candidates and their product pipelines, Zalicus identified Epirus as an organization with the potential to create significant โ€ฆSee details»

EPIRUS Announces Reprioritization of Pipeline to Solely Focus on ...

BOSTON, May 09, 2016 (GLOBE NEWSWIRE) -- EPIRUS Biopharmaceuticals, Inc. (Nasdaq:EPRS), a biosimilar company focused on the global development and โ€ฆSee details»

Epirus files for bankruptcy protection and hands Remicade biosim โ€ฆ

Jul 26, 2016 Epirus Biopharmaceuticals has filed for Chapter 7 bankruptcy protection, settled with licensee Livzon Mabpharm and handed its Remicade (infliximab) biosimilar to Reliance โ€ฆSee details»

linkstock.net © 2022. All rights reserved